Company Cash on Hand: NovaBay (NBY)

NovaBay Pharmaceuticals is developing the Avenova brand within the eye health segment, focusing on blepharitis therapy. The cash position history on the GURU.Markets chart reflects liquidity dynamics, where the value of 0.00 serves as the baseline indicator. NovaBay Pharmaceuticals generates revenue from the sale of antiseptics via pharmacies and online channels, having fully outsourced distribution to external operators to optimize costs.
Analytical breakdowns for NovaBay Pharmaceuticals

Amid intense price competition in the antiseptic segment, it is critical for NovaBay Pharmaceuticals (NBY) to maintain sufficient liquidity to protect revenue. This metric measures the volume of available cash, allowing for an assessment of the issuer's resilience to market shocks and its ability to service debt without external borrowing. By analyzing changes in cash levels, an investor determines the balance between financial security and the risk of inefficient capital utilization.